The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) (NCT04447768)

🧪 Interventions in This Study

• Obinutuzumab (DRUG)
• Venetoclax (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (8 Sites)

• Stanford University Medical Center (Data collection only) — Stanford, California
• Memorial Sloan Kettering Basking Ridge (All protocol activities) — Basking Ridge, New Jersey
• Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown, New Jersey
• Memorial Sloan Kettering Commack (All protocol activities) — Commack, New York
• Memorial Sloan Kettering Westchester (All protocol activities) — Harrison, New York
• Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
• Memorial Sloan Kettering Nassau (All protocol activities) — Uniondale, New York
• University of North Carolina — Chapel Hill, North Carolina

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Lymphocytic Leukemia (CLL)

• Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax — Basking Ridge, New Jersey
• A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies — New York, New York
• Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL — Stamford, Connecticut
• A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) — Houston, Texas
• Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib — Bethesda, Maryland

Explore by condition: All Chronic Lymphocytic Leukemia (CLL) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.